OBJECTIVE： To evaluate the effectiveness and safety of the Xingnao Kaiqiao needling method for treating acute ischemic stroke.DATA SOURCES： We retrieved relevant randomized controlled trials involving Xingnao Kaiqia...OBJECTIVE： To evaluate the effectiveness and safety of the Xingnao Kaiqiao needling method for treating acute ischemic stroke.DATA SOURCES： We retrieved relevant randomized controlled trials involving Xingnao Kaiqiao acupuncture for treatment of acute ischemic stroke. The China National Knowledge Infrastructure, Weipu Information Resources System, Wanfang Medical Data System, Chinese Biomedical Literature Database, Cochrane Library, and Pub Med were searched from June 2006 to March 2016.DATA SELECTION： We analyzed randomized and semi-randomized clinical controlled trials that compared Xingnao Kaiqiao acupuncture with various control treatments, such as conventional drugs or other acupuncture therapies, for treatment of acute ischemic stroke. The quality of articles was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions（Version 5.1）, and the study was carried out using Cochrane system assessment methods. Rev Man 5.2 was used for the meta-analysis of the included studies.OUTCOME MEASURES： The mortality rate, disability rate, activities of daily living（Barthel Index）, and clinical efficacy were observed.RESULTS： Twelve studies met the inclusion criteria for this review. The meta-analysis showed that between Xingnao Kaiqiao acupuncture and the control treatment, Xingnao Kaiqiao acupuncture reduced the disability rate [risk ratio（RR） = 0.51, 95% confidence interval（CI） = 0.27-0.98, z = 2.03, P 〈 0.05], elevated the activities of daily living（weighted mean difference = 12.23, 95% CI： 3.66-20.08, z = 2.80, P 〈 0.005）, and had greater clinical efficacy（RR = 1.61, 95% CI： 1.23-2.09, z = 3.53, P 〈 0.0004）. However, there was no significant difference in mortality rate（RR = 0.61, 95% CI： 0.15-2.45, z = 0.70, P 〉 0.05）. CONCLUSION： The Xingnao Kaiqiao needling method is effective and safe for acute ischemic stroke. However, there was selective bias in this study, and the likelihood of measurement bias is high. Thus, more high-quality randomized controlled trials are needed to provide reliable evidence of the efficacy and safety of Xingnao Kaiqiao acupuncture in the treatment of acute ischemic stroke.展开更多
<strong>Objective:</strong> The objective is to explore the long-term efficacy of total enteral nutrition in the treatment of abdominal abscess in Crohn’s disease. <strong>Methods: </strong>Pa...<strong>Objective:</strong> The objective is to explore the long-term efficacy of total enteral nutrition in the treatment of abdominal abscess in Crohn’s disease. <strong>Methods: </strong>Patients treated with EEN in our hospital and whose abdominal abscess disappeared after 12 weeks of treatment were included, and the data of abscess recurrence and surgical treatment during follow-up were included. <strong>Results:</strong> A total of 44 consecutive cases meeting the criteria were included. The 1-year and 2-year recurrence rates were 22.5% and 39.9% respectively. Among the patients with recurrence, 10 patients chose EEN treatment again, and 5 patients received direct surgical treatment. Of the patients who chose to undergo EEN treatment again, 8 still eventually required surgery. The 1-year operative rate was 16.9%, and the 2-year operative rate was 35.6%. The median operative time was 33.3 (95% CI: 21.3, 45.4) months. <strong>Conclusions: </strong>The 2-year cumulative incidence of recurrence of abdominal abscess in CD patients whose abdominal abscess disappeared after EEN was 39.9%, and the 2-year cumulative surgical rate was 35.6%. The operative stomy rate decreased after EEN, and the primary anastomosis rate increased significantly.展开更多
目的系统评价吡非尼酮对特发性肺纤维化(IPF)的疗效及不良反应。方法在Pubmed、Web Of Science、CNKI、万方、维普检索1999年—2022年发表的以吡非尼酮为干预措施治疗IPF的随机对照试验。按Cochrane系统评价方法,评价纳入研究的方法学...目的系统评价吡非尼酮对特发性肺纤维化(IPF)的疗效及不良反应。方法在Pubmed、Web Of Science、CNKI、万方、维普检索1999年—2022年发表的以吡非尼酮为干预措施治疗IPF的随机对照试验。按Cochrane系统评价方法,评价纳入研究的方法学质量并进行统计分析,采用RevMan5.3进行Meta分析。结果最终纳入13篇文献,合计2088例病例。Meta分析结果表示,与对照组相比,吡非尼酮组的肺功能主要指标用力肺活量(FVC)的改善程度明显高于对照组,差异有统计学意义[SMD=1.03,95%CI(0.81,1.24),P<0.001],第一秒用力肺活量(FEV1)的改变[SMD=0.96,95%CI(0.77,1.16),P<0.001]、一氧化碳弥散量(DLCO)的改变[SMD=0.30,95%CI(0.09,0.51),P=0.005]、PaO2的改变[SMD=0.57,95%CI(0.28,0.86),P<0.001]等次要指标比较,差异有统计学意义(P<0.05);吡非尼酮组的皮疹[RR=2.81,95%CI(2.17,3.65),P<0.001]、头晕[RR=1.59,95%CI(1.21,2.09),P<0.001]、胃肠道反应[RR=1.87,95%CI(1.65,2.12),P<0.001]等不良反应发生率与对照组比较,差异有统计学意义(P<0.05)。结论吡非尼酮能有效延缓IPF患者的肺功能恶化,用药后出现的不良反应多为皮疹、头晕及胃肠道不良反应等,但不良反应较轻,患者可耐受。展开更多
基金supported by the Support Program(Ⅱ)of Hundreds of Universities Outstanding Innovative Talents in Hebei Province of China,No.BR2-104
文摘OBJECTIVE： To evaluate the effectiveness and safety of the Xingnao Kaiqiao needling method for treating acute ischemic stroke.DATA SOURCES： We retrieved relevant randomized controlled trials involving Xingnao Kaiqiao acupuncture for treatment of acute ischemic stroke. The China National Knowledge Infrastructure, Weipu Information Resources System, Wanfang Medical Data System, Chinese Biomedical Literature Database, Cochrane Library, and Pub Med were searched from June 2006 to March 2016.DATA SELECTION： We analyzed randomized and semi-randomized clinical controlled trials that compared Xingnao Kaiqiao acupuncture with various control treatments, such as conventional drugs or other acupuncture therapies, for treatment of acute ischemic stroke. The quality of articles was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions（Version 5.1）, and the study was carried out using Cochrane system assessment methods. Rev Man 5.2 was used for the meta-analysis of the included studies.OUTCOME MEASURES： The mortality rate, disability rate, activities of daily living（Barthel Index）, and clinical efficacy were observed.RESULTS： Twelve studies met the inclusion criteria for this review. The meta-analysis showed that between Xingnao Kaiqiao acupuncture and the control treatment, Xingnao Kaiqiao acupuncture reduced the disability rate [risk ratio（RR） = 0.51, 95% confidence interval（CI） = 0.27-0.98, z = 2.03, P 〈 0.05], elevated the activities of daily living（weighted mean difference = 12.23, 95% CI： 3.66-20.08, z = 2.80, P 〈 0.005）, and had greater clinical efficacy（RR = 1.61, 95% CI： 1.23-2.09, z = 3.53, P 〈 0.0004）. However, there was no significant difference in mortality rate（RR = 0.61, 95% CI： 0.15-2.45, z = 0.70, P 〉 0.05）. CONCLUSION： The Xingnao Kaiqiao needling method is effective and safe for acute ischemic stroke. However, there was selective bias in this study, and the likelihood of measurement bias is high. Thus, more high-quality randomized controlled trials are needed to provide reliable evidence of the efficacy and safety of Xingnao Kaiqiao acupuncture in the treatment of acute ischemic stroke.
文摘<strong>Objective:</strong> The objective is to explore the long-term efficacy of total enteral nutrition in the treatment of abdominal abscess in Crohn’s disease. <strong>Methods: </strong>Patients treated with EEN in our hospital and whose abdominal abscess disappeared after 12 weeks of treatment were included, and the data of abscess recurrence and surgical treatment during follow-up were included. <strong>Results:</strong> A total of 44 consecutive cases meeting the criteria were included. The 1-year and 2-year recurrence rates were 22.5% and 39.9% respectively. Among the patients with recurrence, 10 patients chose EEN treatment again, and 5 patients received direct surgical treatment. Of the patients who chose to undergo EEN treatment again, 8 still eventually required surgery. The 1-year operative rate was 16.9%, and the 2-year operative rate was 35.6%. The median operative time was 33.3 (95% CI: 21.3, 45.4) months. <strong>Conclusions: </strong>The 2-year cumulative incidence of recurrence of abdominal abscess in CD patients whose abdominal abscess disappeared after EEN was 39.9%, and the 2-year cumulative surgical rate was 35.6%. The operative stomy rate decreased after EEN, and the primary anastomosis rate increased significantly.
文摘目的系统评价吡非尼酮对特发性肺纤维化(IPF)的疗效及不良反应。方法在Pubmed、Web Of Science、CNKI、万方、维普检索1999年—2022年发表的以吡非尼酮为干预措施治疗IPF的随机对照试验。按Cochrane系统评价方法,评价纳入研究的方法学质量并进行统计分析,采用RevMan5.3进行Meta分析。结果最终纳入13篇文献,合计2088例病例。Meta分析结果表示,与对照组相比,吡非尼酮组的肺功能主要指标用力肺活量(FVC)的改善程度明显高于对照组,差异有统计学意义[SMD=1.03,95%CI(0.81,1.24),P<0.001],第一秒用力肺活量(FEV1)的改变[SMD=0.96,95%CI(0.77,1.16),P<0.001]、一氧化碳弥散量(DLCO)的改变[SMD=0.30,95%CI(0.09,0.51),P=0.005]、PaO2的改变[SMD=0.57,95%CI(0.28,0.86),P<0.001]等次要指标比较,差异有统计学意义(P<0.05);吡非尼酮组的皮疹[RR=2.81,95%CI(2.17,3.65),P<0.001]、头晕[RR=1.59,95%CI(1.21,2.09),P<0.001]、胃肠道反应[RR=1.87,95%CI(1.65,2.12),P<0.001]等不良反应发生率与对照组比较,差异有统计学意义(P<0.05)。结论吡非尼酮能有效延缓IPF患者的肺功能恶化,用药后出现的不良反应多为皮疹、头晕及胃肠道不良反应等,但不良反应较轻,患者可耐受。
